[Skip to Navigation]
Sign In
June 4, 2020

Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma

Author Affiliations
  • 1Department of Oncology, Juravinski Hospital and Cancer Centre–Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
JAMA Oncol. 2020;6(7):989-991. doi:10.1001/jamaoncol.2020.1303

The malignant lymphomas are a heterogeneous group of blood cancers that have distinctive biologic features and overlapping clinical presentations. All are associated with important risks of morbidity and mortality, and yet all also have well-developed treatment pathways that offer therapeutic benefit, including curative potentials. Systemic therapies, including immunotherapies, together with the judicious use of radiotherapy are the mainstays of treatment. For some groups, autologous hematopoietic cell transplant (HCT) offers curative or highly valuable palliative potential when there is progressive lymphoma after initial therapy.1 Allogeneic HCT may offer curative potential for patients who have progressive lymphoma after receiving these treatments.2 The primary mechanism of action leading to benefit from allogeneic HCT is through immunologic pathways associated with graft-vs-lymphoma effects.3

Add or change institution